Meeting Report
Role of the Advanced Practitioner in the Management of Oral Chemotherapy for Adults With AML
Ashley Leak Bryant,(1) PhD, RN, OCN®, FAAN, and Kaitlyn Buhlinger,(2) PharmD, BCOP, CPP
From (1)UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina; (2)University of North Carolina Medical Center and University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2022;13(3):333–336 |
https://doi.org/10.6004/jadpro.2022.13.3.31 |
© 2022 Harborside™
ABSTRACT
Recent advances have resulted in an expansion of treatment options for AML, especially targeted therapies and low-intensity regimens. At JADPRO Live Virtual 2021, presenters reviewed novel and targeted oral chemotherapy for adults with AML and discussed multidisciplinary collaboration for patients with complex AML chemotherapy regimens.
For access to the full length article, please
sign in.
